Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

Respiratory Medicine

Volumn 104, Issue 4, 2010, Pages 542-549

  Lee, Ji Hyun ^a   Lee, Young Kyung ^b   Kim, Eun Kyung ^a   Kim, Tae Hyung ^c   Huh, Jin Won ^d   Kim, Woo Jin ^e   Lee, Jin Hwa ^f   Lee, Sang Min ^g   Lee, Sangyeub ^h   Lim, Seong Yong ⁱ   Shin, Tae Rim ^j   Yoon, Ho Il ^k   Sheen, Seung Soo ^l   Kim, NamKug ^m   Seo, Joon Beom ^m   Oh, Yeon Mok ^m   Lee, Sang Do ^m  

^a Bundang CHA Hospital   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Hanyang University Guri Hospital   (South Korea)

^d Inje University   (South Korea)

^e Kangwon National University   (South Korea)

^f Mokdong Hospital   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

^h Seoul National University College of Medicine   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j Hallym University College of Medicine   (South Korea)

^k Seoul National University Bundang Hospital   (South Korea)

^l Ajou University School of Medicine   (South Korea)

^m Asan Medical Center   (South Korea)

more..

Author keywords

COPD; Corticosteroid; Inhaled long acting bronchodilator; Subtype

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; BETA 2 ADRENERGIC RECEPTOR; BRONCHODILATING AGENT;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DRUG RESPONSE; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; CLASSIFICATION; DRUG ADMINISTRATION; DRUG EFFECTS; DYSPNEA; INHALATIONAL DRUG ADMINISTRATION; KOREA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ANALYSIS OF VARIANCE; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; KOREA; MALE; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RECEPTORS, ADRENERGIC, BETA-2; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 77649179376     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.10.024     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease updated 2003. Bethesda, MD: National Heart, Lung and Blood Institute, World Health Organization; 2003.
2. Burrows B., Fletcher C.M., Heard B.E., Jones N.L., and Wootliff J.S. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1 (1966) 830-835
3. Calverley P.M.A., and Bellamy D. The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction?. Thorax 55 (2000) 78-82
4. O'Donnell R.A., Peebles C., Ward J.A., et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59 (2004) 837-842
5. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364 (2004) 709-721
6. Callahan C.M., Dittus R.S., and Katz B.P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 114 (1991) 216-223
7. Mahler D., and Wells C. Evaluation of clinical methods for rating dyspnea. Chest 93 (1988) 580-586
8. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
9. Lee Y.K., Oh Y.M., Lee J.H., et al., KOLD Study Group. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung 186 (2008) 157-165
10. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
11. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J 16 (1993) S5-S40
12. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique: 1995 update. Am J Respir Crit Care Med 152 (1995) 2185-2198
13. Snoeck-Stroband J.B., Lapperre T.S., Gosman M.M., et al., Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOD) study group. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 31 (2008) 70-77
14. Kitaguchi Y., Fujimoto K., Kubo K., and Honda T. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 100 (2006) 1742-1752
15. Fujimoto K., Kitaguchi Y., Kubo K., and Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology 11 (2006) 731-740
16. Pistolesi M., Camiciottoli G., Paoletti M., et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 102 (2008) 367-376
17. Boschetto P., Quintavalle S., Zeni E., et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 61 (2006) 1037-1042
18. Buist A.S., Connett J.E., Miller R.D., Kanner R.E., Owens G.R., Voelker H.T., and Chronic Obstructive Pulmonary Disease early intervention trial (Lung Health Study). Baseline characteristics of randomized participants. Chest 103 (1993) 1863-1872
19. Nakano Y., Muro S., Sakai H., et al. Computed tomographic measurements of airway dimensions and emphysema in smokers: correlation with lung function. Am J Respir Crit Care Med 162 (2000) 1102-1108
20. de Jong P.A., Muller N.L., Pare P.D., and Coxson H.O. Computed tomographic imaging of the airways: relationship to structure and function. Eur Respir J 26 (2005) 140-152
21. Hasegawa M., Nasuhara Y., Onodera Y., et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 (2006) 1309-1315
22. King G.G., Muller N.L., Whittall K.P., Xiang Q.S., and Pare P.D. An analysis algorithm for measuring airway lumen and wall areas from high resolution computed tomographic data. Am J Respir Crit Care Med 161 (2000) 574-580
23. Gevenois P.A., de Maertelaer V., De Vuyst P., Zanen J., and Yernault J.C. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 152 (1995) 653-657
24. Gevenois P.A., De Vuyst P., de Maertelaer V., et al. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 154 (1996) 187-192
25. Madani A., Zanen J., de Maertelaer V., and Gevenois P.A. Pulmonary emphysema: objective quantification at multi-detector row CT-comparison with macroscopic and microscopic morphometry. Radiology 238 (2006) 1036-1043
26. Muller N.L., Staples C.A., Miller R.R., and Abboud R.T. "Density mask". An objective method to quantitate emphysema using computed tomography. Chest 94 (1988) 782-787
27. Makita H., Nasuhara Y., Betsuyaku T., Onodera Y., Hizawa N., Nishimura M., and Hokkaido COPD Cohort Study Group. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 62 (2007) 932-937
28. Sanders C., Nath P.H., and Bailey W.C. Detection of emphysema with computed tomography: correlation with pulmonary function tests and chest radiography. Invest Radiol 23 (1988) 262-266
29. Perng D.W., Wu C.C., Su K.C., Lee Y.C., Perng R.P., and Tao C.W. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility. Lung 184 (2006) 217-222
30. Perng D.W., Huang H.Y., Chen H.M., Lee Y.C., and Perng R.P. Characteristics of airway inflammation and bronchodilator reversibility in COPD. Chest 126 (2004) 375-381
31. Tashkin D., and Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 123 (2003) 1441-1449
32. Calverley P., Pauwels R., Vestbo J., et al. Trial of inhaled steroids and long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
33. Calverley P., Anderson J.A., Celli B., et al., TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789